EXELIXIS, INC. EXEL revenue by segment, product and geography
In its fiscal year ending 2025-12-31, EXELIXIS, INC. reported revenue across 1 business segments; the largest, Reportable Segment, was $2.32B, 100.0% of the filed sum (+7.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$2.32B100.0%+7.0% yoy
Members sum to the consolidated $2.32B for this period.
- Product Gross$3.01Bshare n/a+19.6% yoy
- Product$2.12Bshare n/a+17.3% yoy
- Cabometyx$2.11Bshare n/a+17.5% yoy
- Product Sales Discounts And Allowances-$889Mshare n/a+25.4% yoy
- License$214Mshare n/a-38.6% yoy
- Collaboration$197Mshare n/a-45.1% yoy
- Service-$17.1Mshare n/a-269.5% yoy
- Cometriq$9.44Mshare n/a-15.4% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$2.14B92.3%+17.4% yoy
- Europe$154M6.6%-51.6% yoy
- Japan$25.6M1.1%-5.5% yoy
Members sum to the consolidated $2.32B for this period.
- Reportable Segment$611M100.0%+10.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.